UBC, a biopharmaceutical company providing integrated clinical, safety and commercialization services, has acquired Examoto, LLC, a risk evaluation and mitigation strategy (REMS) company. Examoto is dedicated to the design, development, deployment and streamlined operation of technologically driven REMS services in the pharmaceutical market. Transaction terms were not disclosed.

“We are excited by the compelling opportunities this acquisition presents to expand the industry’s leading one-stop-shop for full-service REMS programs,” said Patrick Lindsay, president and CEO, UBC. “The combination of Examoto’s technology-driven approach with UBC’s scientific, technological and operational expertise will ensure the most efficient delivery of successful REMS programs to patients and clients.”

Jason Leedy, Examoto’s founder, said, “Examoto’s technology and design innovations, in concert with UBC’s project management office and related REMS services, creates a REMS powerhouse. We will collectively have the most comprehensive, proven capabilities for risk mitigation solutions for the pharma industry. This strategic combination will encourage efficiency, quality, creativity, and synergy across the various REMS workflows and will provide sponsors with a single point of responsibility for their clinical programs.”

Natalie O’Donnell, corporate vice president, UBC safety and risk management, said, “Today’s healthcare market increasingly demands evidence of drug safety and effectiveness to ensure sufficient validation. Our acquisition of Examoto helps cement UBC’s status as a preeminent leader in this category with a full-service REMS solution that leverages enhanced technologies and product innovations to help mitigate safety risk while optimizing the commercialization and delivery of products to market.”